Cargando…
Punicalagin Ameliorates Lupus Nephritis via Inhibition of PAR2
Lupus nephritis (LN) is the most frequent phenotype in patients with systemic lupus erythematosus (SLE) and has a high rate of progression to end-stage renal disease, in spite of intensive treatment and maintenance therapies. Recent evidence suggests that protease-activated receptor-2 (PAR2) is a th...
Autores principales: | Seo, Yohan, Mun, Chin Hee, Park, So-Hyeon, Jeon, Dongkyu, Kim, Su Jeong, Yoon, Taejun, Ko, Eunhee, Jo, Sungwoo, Park, Yong-Beom, Namkung, Wan, Lee, Sang-Won |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7404282/ https://www.ncbi.nlm.nih.gov/pubmed/32674502 http://dx.doi.org/10.3390/ijms21144975 |
Ejemplares similares
-
Cinobufagin Exerts Anticancer Activity in Oral Squamous Cell Carcinoma Cells through Downregulation of ANO1
por: Jo, Sungwoo, et al.
Publicado: (2021) -
GB83, an Agonist of PAR2 with a Unique Mechanism of Action Distinct from Trypsin and PAR2-AP
por: Heo, Yunkyung, et al.
Publicado: (2022) -
VI-116, A Novel Potent Inhibitor of VRAC with Minimal Effect on ANO1
por: Jeon, Dongkyu, et al.
Publicado: (2022) -
Non-histologic factors discriminating proliferative lupus nephritis from membranous lupus nephritis
por: Kwon, Oh Chan, et al.
Publicado: (2020) -
Worse Renal Presentation and Prognosis in Initial-Onset Lupus Nephritis than Early-Onset Lupus Nephritis
por: Kwon, Oh Chan, et al.
Publicado: (2020)